Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases

Yang, Annie; Zhang, Zhifang; Chaurasiya, Shyambabu; Park, Anthony K.; Lu, Jianming; Kim, Sang-In; Valencia, Hannah; Fong, Yuman; Woo, Yanghee

doi:10.1016/j.omto.2023.100734

Cited by 2 publications

(4 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, Yang et al [ 65 ] investigated the effect of CF17, a new replication-competent chimeric poxvirus that they administered to intestinal and diffuse GC cell lines. They found that CF17 could infect, and kill cancer cells in dose- and time-dependent manners in vitro .…”

Section: Treatment Modalitiesmentioning

confidence: 99%

“…In parallel, in the in vivo experiments, CF17 treatment resulted in a reduction in tumor burden, prevention of ascites formation, and prolonged survival of the experimental animals. These experimental results suggest that CF17 may be used in future studies to treat patients with GC and malignant ascites[ 65 ]. In a very recent study, the same group of investigators demonstrated that CF33 oncolytic viruses are capable of delivering functional proteins and demonstrating effective antitumor activity in GCPM models when administered intraperitoneally, suggesting that similar studies in GC patients with peritoneal metastases can be designed and performed in the future[ 66 ].…”

Section: Treatment Modalitiesmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy of gastric cancer: Present status and future perspectives

Triantafillidis,

Konstadoulakis,

Papalois

2024

World J Gastroenterol

View full text Add to dashboard Cite

In this editorial, we comment on the article entitled “Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023),” which was published in the recent issue of the World Journal of Gastroenterology . We focused on the results of the authors’ bibliometric analysis concerning gastric cancer immunotherapy, which they analyzed in depth by compiling the relevant publications of the last 20 years. Before that, we briefly describe the most recent data concerning the epidemiological parameters of gastric cancer (GC) in different countries, attempting to give an interpretation based on the etiological factors involved in the etiopathogenesis of the neoplasm. We then briefly discuss the conservative treatment (chemotherapy) of the various forms of this malignant neoplasm. We describe the treatment of resectable tumors, locally advanced neoplasms, and unresectable (advanced) cases. Special attention is given to modern therapeutic approaches with emphasis on immunotherapy, which seems to be the future of GC treatment, especially in combination with chemotherapy. There is also a thorough analysis of the results of the study under review in terms of the number of scientific publications, the countries in which the studies were conducted, the authors, and the scientific centers of origin, as well as the clinical studies in progress. Finally, an attempt is made to draw some con-clusions and to point out possible future directions.

show abstract

Section: Treatment Modalitiesmentioning

confidence: 99%

Section: Treatment Modalitiesmentioning

confidence: 99%

Immunotherapy of gastric cancer: Present status and future perspectives

Triantafillidis,

Konstadoulakis,

Papalois

2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…52 54 55 Although no study has portrayed alterations for viruses in gastric carcinogenesis, modified viruses can be used to deliver therapeutic transgenes with selective replication in tumour cells, thereby inhibiting GC and enhancing treatment efficacy. [69][70][71] For instance, oncolytic herpes simplex virus armed with thrombospondin-1 harbours antitumour efficacy through direct viral oncolysis and antiangiogenesis in GC. 69 The delivery of tumour-suppressor gene TIPE2 into GC cells by adenovirus could inhibit cancer metastasis in mice.…”

Section: Beneficial Fungus and Virus In Gastric Carcinogenesismentioning

confidence: 99%

“…70 Chimeric oncolytic poxvirus CF17 directs peritonea to prevent malignant ascites and improve survival of mice with GC peritoneal metastases. 71 To date, most GC-depleted fungi and viruses are unexplored for their roles in cancer; hence,…”

Section: Beneficial Fungus and Virus In Gastric Carcinogenesismentioning

confidence: 99%

Stomach microbiota in gastric cancer development and clinical implications

Zeng,

Gou,

Lau

et al. 2024

Gut

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies and a prominent cause of cancer mortality worldwide. A distinctive characteristic of GC is its intimate association with commensal microbial community. AlthoughHelicobacter pyloriis widely recognised as an inciting factor of the onset of gastric carcinogenesis, increasing evidence has indicated the substantial involvement of microbes that reside in the gastric mucosa during disease progression. In particular, dysregulation in gastric microbiota could play pivotal roles throughout the whole carcinogenic processes, from the development of precancerous lesions to gastric malignancy. Here, current understanding of the gastric microbiota in GC development is summarised. Potential translational and clinical implications of using gastric microbes for GC diagnosis, prognosis and therapeutics are also evaluated, with further discussion on conceptual haziness and limitations at present. Finally, we highlight that modulating microbes is a novel and promising frontier for the prevention and management of GC, which necessitates future in-depth investigations.

show abstract

Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases

Cited by 2 publications

References 29 publications

Immunotherapy of gastric cancer: Present status and future perspectives

Immunotherapy of gastric cancer: Present status and future perspectives

Stomach microbiota in gastric cancer development and clinical implications

Contact Info

Product

Resources

About